Search


Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
4 days ago13 min read



